Human IL-13 R alpha 2 Antibody

AF146 23 Citations Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
AF146
AF146-SP

Bulk Orders

Human IL-13 R alpha 2 Antibody in Western Blot

3 Images

Product Details

Citations (23)

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human IL-13 R alpha 2 Antibody Summary

Species Reactivity

Human

Specificity

Detects human IL-13 R alpha 2 in direct ELISAs and Western blots. In direct ELISAs, approximately 5% cross-reactivity with recombinant mouse IL-13 R alpha 2 is observed and less than 1% cross-reactivity with recombinant human IL-13 R alpha 1 is observed.

Source

Polyclonal Goat IgG

Purification

Antigen Affinity-purified

Immunogen

Mouse myeloma cell line NS0-derived recombinant human IL‑13 R alpha 2
Cys22-Leu342
Accession # Q14627

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Western Blot

0.2 µg/mL

See below

Simple Western

10 µg/mL

See below

Flow Cytometry

2.5 µg/10⁶ cells

A375 human melanoma cell line

Immunohistochemistry

5-15 µg/mL

See below

Blockade of Receptor-ligand Interaction

In a functional ELISA, 2-6 µg/mL of this antibody will block 50% of the binding of 100 ng/mL of Recombinant Human IL-13 (Catalog # 213‑ILB) to immobilized Recombinant Human IL-13 R alpha 2 Fc Chimera (Catalog # 614-INS) coated at 4 µg/mL (100 µL/well). At 40 μg/mL, this antibody will block >90% of the binding.

CyTOF-ready

Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Data Examples

Western Blot

View Larger

Detection of Human IL‑13 R alpha 2 by Western Blot. Western blot shows lysates of human placenta tissue and human testis tissue. PVDF membrane was probed with 0.2 µg/mL of Goat Anti-Human IL-13 Ra2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF146) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for IL-13 Ra2 at approximately 50-55 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Immunohistochemistry

View Larger

IL-13 R alpha 2 in Human Prostate Cancer Tissue. IL-13 Ra2 was detected in immersion fixed paraffin-embedded sections of human prostate cancer tissue using Goat Anti-Human IL-13 Ra2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF146) at 5 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to glandular epithelial cells. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Simple Western

View Larger

Detection of Human IL‑13 R alpha 2 by Simple Western^TM. Simple Western lane view shows lysates of human placenta tissue and human testis tissue, loaded at 0.2 mg/mL. A specific band was detected for IL-13 Ra2 at approximately 40 kDa (as indicated) using 10 µg/mL of Goat Anti-Human IL-13 Ra2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF146) followed by 1:50 dilution of HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS.

Reconstitution Buffer Available

Reconstitution Buffer 1 (PBS)

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IL-13 R alpha 2

Two type1 membrane proteins belonging to the hemopoietin receptor family have been cloned and shown to bind IL-13 with differing affinities. The lower affinity IL-13 binding protein, previously designated IL-13 R alpha, IL-13 R alpha ^lor NR4, is now referred to as IL-13 R alpha 1. The high affinity IL-13 binding protein, previously also designated IL-13 R or IL-13 R alpha ^l, is now referred to as IL-13 R alpha 2. Human IL-13 R alpha 2 was originally cloned from the Caki-1 human renal carcinoma cell line. The IL-13 R alpha 2 cDNA encodes a 380 amino acid (aa) residue precursor protein with a putative 26 aa residue signal peptide, a 317 residue extracellular domain, a 20 aa residue transmembrane region and a 17 aa residue cytoplasmic tail. Human and mouse IL‑13 R alpha 2 share 59% aa sequence identity. The extracellular domain of IL-13 R alpha 2 is also closely related to that of IL-13 R alpha 1. However, the 17 aa residue cytoplasmic domain of IL-13 R alpha 2 is much shorter than that of IL-13 R alpha 1, suggesting that the two receptors are functionally distinct. IL-13 R alpha 1 has been shown to combine with the IL-4 R to form a high-affinity receptor complex capable of transducing an IL‑13‑dependent proliferative signal. The role of IL-13 R alpha 2 in IL-13 signaling remains to be elucidated. The amino-terminal 27 aa residues of the human and mouse IL‑13 R alpha 2 are nearly identical to that of a soluble mouse IL-13 binding protein purified from mouse serum and urine.

References

Caput, D. et al. (1996) J. Biol. Chem. 271:16921.
Donaldson, D.D. et al. (1998) J. Immunol. 161:2317.
Aman, M.J. et al. (1996) J. Biol. Chem. 271:29265.
Hilton, D.J. et al. (1996) Proc. Natl. Acad. Sci. USA 93:497.
Zhang, J.G. et al. (1997) J. Biol. Chem. 272:9474.

Long Name

Interleukin 13 Receptor alpha 2

Entrez Gene IDs

3598 (Human); 16165 (Mouse)

Alternate Names

cancer/testis antigen 19; CD213a2 antigen; CD213a2; CT19; IL-13 R alpha 2; IL-13 receptor subunit alpha-2; IL13BP; IL13R alpha 2; IL-13R subunit alpha-2; IL13R; IL-13R; IL13RA2; IL-13Ra2; IL-13R-alpha-2; interleukin 13 binding protein; interleukin 13 receptor alpha 2 chain; interleukin 13 receptor, alpha 2; interleukin-13 receptor subunit alpha-2; Interleukin-13-binding protein

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citations for Human IL-13 R alpha 2 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

23 Citations: Showing 1 - 10
Filter your results:

Filter by:

Identification of a novel role of IL-13R?2 in human Glioblastoma multiforme: interleukin-13 mediates signal transduction through AP-1 pathway
Authors: R Bhardwaj, A Suzuki, P Leland, BH Joshi, RK Puri
J Transl Med, 2018;16(1):369.
Species: Human
Sample Types: Whole Cells
Applications: ICC
Optimization of IL13R?2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma
Authors: CE Brown, B Aguilar, R Starr, X Yang, WC Chang, L Weng, B Chang, A Sarkissian, A Brito, JF Sanchez, JR Ostberg, M D'Apuzzo, B Badie, ME Barish, SJ Forman
Mol. Ther., 2018;26(1):31-44.
Species: Human
Sample Types: Xenograft
Applications: Flow Cytometry
IL-13 receptors as possible therapeutic targets in diffuse intrinsic pontine glioma
Authors: NE Berlow, MN Svalina, MJ Quist, TP Settelmeye, V Zherebitsk, M Kogiso, L Qi, Y Du, CE Hawkins, E Hulleman, XN Li, SH Gultekin, C Keller
PLoS ONE, 2018;13(4):e0193565.
Species: Human
Sample Types: Whole Tissue
Applications: IHC
IL-4 primes the dynamics of breast cancer progression via DUSP4 inhibition
Authors: M Gaggianesi, A Turdo, A Chinnici, E Lipari, T Apuzzo, A Benfante, I Sperduti, S Di Franco, S Meraviglia, E Lo Presti, F Dieli, V Caputo, G Militello, S Vieni, G Stassi, M Todaro
Cancer Res., 2017;0(0):.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot
Cigarette smoke extracts induce overexpression of the proto-oncogenic gene interleukin-13 receptor ?2 through activation of the PKA-CREB signaling pathway to trigger malignant transformation of lung vascular endothelial cells and angiogenesis
Authors: Mei Meng
Cell. Signal, 2016;0(0):.
IL-13R?2 uses TMEM219 in chitinase 3-like-1-induced signalling and effector responses
Nat Commun, 2016;7(0):12752.
Species: Human
Sample Types: Cell Lysates
Applications: Immunoprecipitation
Expression of surfactant protein D in airways of asthmatics and interleukin-13 modulation of surfactant protein D in human models of airway epithelium.
Authors: Xu J, Singhera G, Dorscheid D
Respir Res, 2015;16(0):26.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization
Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
Authors: Shibasaki N, Yamasaki T, Kanno T, Arakaki R, Sakamoto H, Utsunomiya N, Inoue T, Tsuruyama T, Nakamura E, Ogawa O, Kamba T
PLoS ONE, 2015;10(6):e0130980.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P
IL-13Ralpha2 mediates PNR-induced migration and metastasis in ERalpha-negative breast cancer.
Authors: Zhao Z, Wang L, Xu W
Oncogene, 2015;34(12):1596-607.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot
Cytokine induction of VCAM-1 but not IL13Ralpha2 on glioma cells: a tale of two antibodies.
Authors: Mahadev V, Starr R, Wright S, Martinez C, Jensen M, Barish M, Forman S, Brown C
PLoS ONE, 2014;9(5):e95123.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry

Absence of a role for interleukin-13 in inflammatory bowel disease.
Authors: Biancheri P, Di Sabatino A, Ammoscato F, Facciotti F, Caprioli F, Curciarello R, Hoque S, Ghanbari A, Joe-Njoku I, Giuffrida P, Rovedatti L, Geginat J, Corazza G, MacDonald T
Eur J Immunol, 2014;44(2):370-85.

Matrix metalloproteinase 8 contributes to solubilization of IL-13 receptor alpha2 in vivo.
Authors: Chen W, Tabata Y, Gibson AM, Daines MO, Warrier MR, Wills-Karp M, Hershey GK
J. Allergy Clin. Immunol., 2008;122(3):625-32.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry

Development of an in vitro potency bioassay for therapeutic IL-13 antagonists: the A-549 cell bioassay.
Authors: Miller R, Sadhukhan R, Wu C
J. Immunol. Methods, 2008;334(1):134-41.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization

Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity.
Authors: Allen C, Paraskevakou G, Iankov I, Giannini C, Schroeder M, Sarkaria J, Schroeder M, Puri RK, Russell SJ, Galanis E
Mol. Ther., 2008;16(9):1556-64.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot

Effect of IL-13 receptor alpha2 levels on the biological activity of IL-13 variant R110Q.
Authors: Andrews AL, Bucchieri F, Arima K, Izuhara K, Holgate ST, Davies DE, Holloway JW
J. Allergy Clin. Immunol., 2007;120(1):91-7.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization

Level of expression of IL-13R alpha 2 impacts receptor distribution and IL-13 signaling.
Authors: Daines MO, Tabata Y, Walker BA, Chen W, Warrier MR, Basu S, Hershey GK
J. Immunol., 2006;176(12):7495-501.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry

IL-13 receptor alpha 2: a regulator of IL-13 and IL-4 signal transduction in primary human fibroblasts.
Authors: Andrews AL, Nasir T, Bucchieri F, Holloway JW, Holgate ST, Davies DE
J. Allergy Clin. Immunol., 2006;118(4):858-65.
Species: Human
Sample Types: Cell Lysates
Applications: Immunoprecipitation

Protection of human conjunctival fibroblasts from NO-induced apoptosis by interleukin-4 or interleukin-13.
Authors: Fujitsu Y, Fukuda K, Kimura K, Seki K, Kumagai N, Nishida T
Invest. Ophthalmol. Vis. Sci., 2005;46(3):797-802.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry

Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo.
Authors: Trieu Y, Wen XY, Skinnider BF, Bray MR, Li Z, Claudio JO, Masih-Khan E, Zhu YX, Trudel S, McCart JA, Mak TW, Stewart AK
Cancer Res., 2004;64(9):3271-5.
Species: Human
Sample Types: Cell Culture Supernates
Applications: Immunoprecipitation

Bioactivity and Safety of IL13Ralpha2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
Authors: Brown C, Badie B, Barish M, Weng L, Ostberg J, Chang W, Naranjo A, Starr R, Wagner J, Wright C, Zhai Y, Bading J, Ressler J, Portnow J, D'Apuzzo M, Forman S, Jensen M
Clin Cancer Res, 0;21(18):4062-72.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry

Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.
Authors: Hegde M, Corder A, Chow K, Mukherjee M, Ashoori A, Kew Y, Zhang Y, Baskin D, Merchant F, Brawley V, Byrd T, Krebs S, Wu M, Liu H, Heslop H, Gottschalk S, Yvon E, Ahmed N
Mol Ther, 0;21(11):2087-101.
Species: Human
Sample Types: Whole Tissue
Applications: CAR-T (IHC-P)

Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape.
Authors: Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai S, Wakefield A, Fousek K, Bielamowicz K, Chow K, Brawley V, Byrd T, Krebs S, Gottschalk S, Wels W, Baker M, Dotti G, Mamonkin M, Brenner M, Orange J, Ahmed N
J Clin Invest, 0;126(8):3036-52.
Species: Human
Sample Types: Whole Cells
Applications: CAR-T (Flow Cytometry)

Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma.
Authors: Bielamowicz K, Fousek K, Byrd T, Samaha H, Mukherjee M, Aware N, Wu M, Orange J, Sumazin P, Man T, Joseph S, Hegde M, Ahmed N
Neuro Oncol, 0;20(4):506-518.
Species: Xenograft
Sample Types: Whole Tissue
Applications: CAR-T (IHC-F)